Progress of immune checkpoint inhibitors in aggressive pituitary adenomas
10.3760/cma.j.cn311282-20210625-00406
- VernacularTitle:免疫检查点抑制剂在治疗侵袭性垂体瘤中的研究进展
- Author:
Yutong XU
1
;
Jianzhong XIAO
Author Information
1. 清华大学附属北京清华长庚医院内分泌科，清华大学临床医学院，北京 102218
- Keywords:
Pituitary adenoma;
Immunotherapy;
Immune checkpoint inhibitors
- From:
Chinese Journal of Endocrinology and Metabolism
2022;38(8):688-691
- CountryChina
- Language:Chinese
-
Abstract:
Pituitary adenomas(PAs) are the most common types of central nervous system tumors. Although most of them are benign tumors, aggressive PAs are resistant to conventional treatments and thus increase morbidity and mortality. Immunotherapy is a promising treatment and has been applied in treatment of kinds of neoplasms, including aggressive PAs. This review summarizes recent advances of immune checkpoint inhibitors in PAs.
